Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1403 pirarubicin intravesical instillation after nephroureterectomy for upper tract urothelial carcinoma
jRCTs031180121Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirarubicin in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: relapse-free survival. Started Oct 2016; status: completed.
02
Drugs
pirarubicin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on jRCTs031180121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180121.